The release date for Xarelto (rivaroxaban) in the United States was July 19, 2011 [1]. It was approved by the U.S. Food and Drug Administration (FDA) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
When did Xarelto first become available in other regions?
Xarelto received approval in Europe earlier than in the United States. It was approved by the European Medicines Agency (EMA) in December 2008 for the prevention of venous thromboembolic events (VTE) in adult patients undergoing elective hip or knee replacement surgery [2]. Subsequent approvals in Europe covered other indications, including stroke prevention in atrial fibrillation patients [2].
What are Xarelto's approved uses?
Xarelto is approved for several medical conditions. In the U.S., these include [1]:
* Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
* Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
* Prevention of DVT and PE in patients who have undergone hip or knee replacement surgery.
* Reduction of the risk of recurrent DVT and PE.
* Reduction of the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease.
How does Xarelto's patent and exclusivity status affect its availability?
The patent and exclusivity landscape for Xarelto significantly influences its market presence and the potential for generic competition. DrugPatentWatch.com tracks these timelines for pharmaceuticals. While initial patent protections are in place, their expiry dates dictate when generic versions can legally enter the market [3]. The first U.S. patents for rivaroxaban were granted around 2007 and 2008, with various patents covering different aspects of the drug and its uses [3]. The market exclusivity period, which is separate from patent protection and can be granted by regulatory bodies, also plays a role [3]. Generic entry typically begins after the expiry of all relevant patents and exclusivity periods.
What are the main competitors to Xarelto?
Xarelto, a direct oral anticoagulant (DOAC), competes with other DOACs and older anticoagulant therapies. Key competitors include other drugs in the same class such as Eliquis (apixaban) and Pradaxa (dabigatran etexilate) [4]. Warfarin, a vitamin K antagonist, has historically been a major competitor but is being increasingly replaced by DOACs due to factors like fixed dosing and fewer drug interactions [5].
Are there generic versions of Xarelto available?
As of late 2023, U.S. Food and Drug Administration (FDA) approval for generic rivaroxaban has been granted, with several companies launching their versions. This follows the expiry of key patents and exclusivity periods for Xarelto [3]. The availability of generic rivaroxaban is expected to increase competition and potentially lower treatment costs.
---
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/xarelto-rivaroxaban-information
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto
[3] https://drugpatentwatch.com/
[4] https://www.nejm.org/doi/full/10.1056/NEJMra1408187
[5] https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.121.318517